PURPOSE: To evaluate the prevalence and risk factors for vision loss in patients with clinical or immunologic AIDS without infectious retinitis. DESIGN: A prospective, multicenter cohort study of patients with AIDS. METHODS: One thousand three hundred and fifty-one patients (2,671 eyes) at 19 clinical trials centers diagnosed with AIDS but without major ocular complications of HIV. Standardized measurements of visual acuity, automated perimetry, and contrast sensitivity were analyzed and correlated with measurements of patients' health and medical data relating to HIV infection. We evaluated correlations between vision function testing and HIV-related risk factors and medical testing. RESULTS: There were significant (P<.05) associations between measures of decreasing vision function and indices of increasing disease severity, including Karnofsky score and hemoglobin. A significant relationship was seen between low-contrast sensitivity and decreasing levels of CD4+ T-cell count. Three percent of eyes had a visual acuity worse than 20/40 Snellen equivalents, which was significantly associated with a history of opportunistic infections and low Karnofsky score. When compared with external groups with normal vision, 39% of eyes had abnormal mean deviation on automated perimetry, 33% had abnormal pattern standard deviation, and 12% of eyes had low contrast sensitivity. CONCLUSIONS: This study confirms that visual dysfunction is common in patients with AIDS but without retinitis. The most prevalent visual dysfunction is loss of visual field; nearly 40% of patients have some abnormal visual field. There is an association between general disease severity and less access to care and vision loss. The pathophysiology of this vision loss is unknown but is consistent with retinovascular disease or optic nerve disease.
PURPOSE: To evaluate the prevalence and risk factors for vision loss in patients with clinical or immunologic AIDS without infectious retinitis. DESIGN: A prospective, multicenter cohort study of patients with AIDS. METHODS: One thousand three hundred and fifty-one patients (2,671 eyes) at 19 clinical trials centers diagnosed with AIDS but without major ocular complications of HIV. Standardized measurements of visual acuity, automated perimetry, and contrast sensitivity were analyzed and correlated with measurements of patients' health and medical data relating to HIV infection. We evaluated correlations between vision function testing and HIV-related risk factors and medical testing. RESULTS: There were significant (P<.05) associations between measures of decreasing vision function and indices of increasing disease severity, including Karnofsky score and hemoglobin. A significant relationship was seen between low-contrast sensitivity and decreasing levels of CD4+ T-cell count. Three percent of eyes had a visual acuity worse than 20/40 Snellen equivalents, which was significantly associated with a history of opportunistic infections and low Karnofsky score. When compared with external groups with normal vision, 39% of eyes had abnormal mean deviation on automated perimetry, 33% had abnormal pattern standard deviation, and 12% of eyes had low contrast sensitivity. CONCLUSIONS: This study confirms that visual dysfunction is common in patients with AIDS but without retinitis. The most prevalent visual dysfunction is loss of visual field; nearly 40% of patients have some abnormal visual field. There is an association between general disease severity and less access to care and vision loss. The pathophysiology of this vision loss is unknown but is consistent with retinovascular disease or optic nerve disease.
Authors: A A Sadun; J S Pepose; M C Madigan; K A Laycock; W N Tenhula; W R Freeman Journal: Graefes Arch Clin Exp Ophthalmol Date: 1995-07 Impact factor: 3.117
Authors: Efe Sezgin; Sher L Hendrickson; Douglas A Jabs; Mark L Van Natta; Richard A Lewis; Jennifer L Troyer; Stephen J O'Brien Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: Partho S Kalyani; Gary N Holland; Amani A Fawzi; Tiago E F Arantes; Fei Yu; Alfredo A Sadun Journal: Am J Ophthalmol Date: 2012-01-15 Impact factor: 5.258
Authors: Sarah H Van Tassel; Paul Petrakos; Elizabeth Marlow; Elizabeth Mauer; Harjot K Singh; Anna M Demetriades Journal: Int J Ophthalmol Date: 2019-05-18 Impact factor: 1.779
Authors: Partho S Kalyani; Amani A Fawzi; Sapna Gangaputra; Mark L van Natta; Larry D Hubbard; Ronald P Danis; Jennifer E Thorne; Gary N Holland Journal: Am J Ophthalmol Date: 2011-10-22 Impact factor: 5.258
Authors: Sarah Cheng; Helaina Klein; Dirk-Uwe Bartsch; Igor Kozak; Thomas D Marcotte; William R Freeman Journal: Graefes Arch Clin Exp Ophthalmol Date: 2011-07-06 Impact factor: 3.117
Authors: Gary N Holland; Peter J Kappel; Mark L Van Natta; Frank J Palella; Alice T Lyon; Kayur H Shah; Peter R Pavan; Douglas A Jabs Journal: Am J Ophthalmol Date: 2010-05 Impact factor: 5.258
Authors: Janet T Holbrook; Ryan Colvin; Mark L van Natta; Jennifer E Thorne; Mark Bardsley; Douglas A Jabs Journal: Am J Ophthalmol Date: 2011-07-13 Impact factor: 5.258
Authors: Sher L Hendrickson; Douglas A Jabs; Mark Van Natta; Richard Alan Lewis; Douglas C Wallace; Stephen J O'Brien Journal: J Acquir Immune Defic Syndr Date: 2010-04-01 Impact factor: 3.731